{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:46:55Z","timestamp":1793641615047,"version":"4.5.1"},"reference-count":26,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,2,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Ponatinib is associated\u00a0with cardiovascular adverse events (CAEs), and its frequency in the real world is limited. In this retrospective study, we examined the survival outcomes and associated toxicities in 78 consecutive ponatinib-treated patients with chronic myeloid leukemia (CML) at the Moffitt Cancer Center from January 2011 through December 2017. The most common non-CAE was thrombocytopenia (39.7%), occurring in a dose-dependent fashion. Eighteen patients (23.1%) experienced some form of CAE, with the most common being arrhythmia (9%) and hypertension (7.7%), whereas 3 patients experienced myocardial infarction (3.8%). Before 2014, most patients were started on ponatinib 45 mg daily. There was an inverse correlation between cardio-oncology referral and the number of CAEs (P\u00a0= .0440); however, a lower ponatinib starting dose, more frequent dose reduction, and increased cardio-oncology referral all were likely to have contributed to the observed decrease in CAEs after 2014. The response rate and 5-year overall survival (OS) were higher than those observed in the Ponatinib Ph+\u00a0ALL and CML Evaluation (PACE) trial (major molecular response, 58.7% vs 40% and OS, 76% vs 73%; median follow-up of 32.5 months). Ponatinib-treated patients with chronic phase\u2013CML did not show a significant improvement with allogeneic stem cell transplantation, whereas those with accelerated phase\/blast phase\u2013CML had a much better outcome (median OS of 32.9 months vs 9.2 months;\u00a0P\u00a0= .01). These results demonstrate that ponatinib is highly effective. Dose adjustments and increased awareness of the cardiotoxicities associated with ponatinib may help maximize its benefits.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019000268","type":"journal-article","created":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T11:36:17Z","timestamp":1581420977000},"page":"530-538","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":92,"title":["Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia"],"prefix":"10.1182","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2872-1961","authenticated-orcid":false,"given":"Onyee","family":"Chan","sequence":"first","affiliation":[{"name":"Department of Medicine, University of South Florida, Tampa, FL;"},{"name":"Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chetasi","family":"Talati","sequence":"additional","affiliation":[{"name":"Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leidy","family":"Isenalumhe","sequence":"additional","affiliation":[{"name":"Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Shams","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of South Florida, Tampa, FL;"},{"name":"Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Nodzon","sequence":"additional","affiliation":[{"name":"Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fradley","sequence":"additional","affiliation":[{"name":"Department of Cardio-Oncology, Moffitt Cancer Center and University of South Florida, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendra","family":"Sweet","sequence":"additional","affiliation":[{"name":"Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Pinilla-Ibarz","sequence":"additional","affiliation":[{"name":"Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,2,11]]},"reference":[{"issue":"5894","key":"2020021111361319900_B1","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/300765a0","article-title":"A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia","volume":"300","author":"de Klein","year":"1982","journal-title":"Nature"},{"key":"2020021111361319900_B2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00277-015-2322-2","article-title":"A review of the European LeukemiaNet recommendations for the management of CML","volume":"94","author":"Baccarani","year":"2015","journal-title":"Ann Hematol"},{"issue":"2","key":"2020021111361319900_B3","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/MOH.0000000000000403","article-title":"Resistance in chronic myeloid leukemia: definitions and novel therapeutic agents","volume":"25","author":"Talati","year":"2018","journal-title":"Curr Opin Hematol"},{"key":"2020021111361319900_B4","first-page":"243","article-title":"Resistant mutations in CML and Ph(+)ALL - role of ponatinib","volume":"8","author":"Miller","year":"2014","journal-title":"Biologics"},{"issue":"5","key":"2020021111361319900_B5","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O\u2019Hare","year":"2009","journal-title":"Cancer Cell"},{"issue":"22","key":"2020021111361319900_B6","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"N Engl J Med"},{"issue":"3","key":"2020021111361319900_B7","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2217\/fon-2018-0371","article-title":"Ponatinib in the treatment of chronic myeloid leukemia and philadelphia chromosome positive acute lymphoblastic leukemia","volume":"15","author":"Pavlovsky","year":"2019","journal-title":"Future Oncol"},{"issue":"21","key":"2020021111361319900_B8","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.1783.1783","article-title":"Comparative TKI Profiling Analyses to Explore Potential Mechanisms of Ponatinib-Associated Arterial Thrombotic Events [abstract]","volume":"124","author":"Rivera","year":"2014","journal-title":"Blood"},{"key":"2020021111361319900_B9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.leukres.2017.05.008","article-title":"Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML","volume":"59","author":"Valent","year":"2017","journal-title":"Leuk Res"},{"issue":"1","key":"2020021111361319900_B10","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/10428194.2018.1466294","article-title":"Bosutinib, dasatinib, imatinib, nilotinib, and ponatinib differentially affect the vascular molecular pathways and functionality of human endothelial cells","volume":"60","author":"Gover-Proaktor","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2020021111361319900_B11","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1080\/10428194.2016.1239258","article-title":"Ponatinib reduces viability, migration, and functionality of human endothelial cells","volume":"58","author":"Gover-Proaktor","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2020021111361319900_B12","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"2020021111361319900_B13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.exphem.2018.08.006","article-title":"Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study","volume":"67","author":"Heiblig","year":"2018","journal-title":"Exp Hematol"},{"issue":"7","key":"2020021111361319900_B14","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/j.clml.2018.05.002","article-title":"Real-life Experience With Ponatinib in Chronic Myeloid Leukemia: A Multicenter Observational Study","volume":"18","author":"Shacham-Abulafia","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"2020021111361319900_B15","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/hon.2606","article-title":"Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart","volume":"37","author":"Caocci","year":"2019","journal-title":"Hematol Oncol"},{"issue":"6","key":"2020021111361319900_B16","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"2020021111361319900_B17","volume-title":"R: A language and environment for statistical computing","author":"The R Core Team","year":"2018"},{"issue":"24","key":"2020021111361319900_B18","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population","volume":"34","author":"Bower","year":"2016","journal-title":"J Clin Oncol"},{"issue":"35","key":"2020021111361319900_B19","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","article-title":"Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia","volume":"33","author":"Moslehi","year":"2015","journal-title":"J Clin Oncol"},{"key":"2020021111361319900_B20","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1182\/asheducation-2017.1.110","article-title":"Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy","volume":"2017","author":"Barber","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"6","key":"2020021111361319900_B21","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/bloodadvances.2018025874","article-title":"Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs","volume":"3","author":"Jain","year":"2019","journal-title":"Blood Adv"},{"issue":"17","key":"2020021111361319900_B22","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/jnci\/djr292","article-title":"Severe peripheral arterial disease during nilotinib therapy","volume":"103","author":"Le Coutre","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"2020021111361319900_B23","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"key":"2020021111361319900_B24","unstructured":"Cortes\n              JE\n            , NicoliniFE, HochhausA, et al Arterial occlusive events (AOEs) in the phase 2 ponatinib PACE trial: 5-year update in heavily treated patients (Pts) with chronic-phase chronic myeloid leukemia (CP-CML) [abstract]. Blood. 2017;130(suppl 1). Abstract 2896."},{"issue":"15","key":"2020021111361319900_B25","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1002\/cncr.30558","article-title":"Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation","volume":"123","author":"Nicolini","year":"2017","journal-title":"Cancer"},{"key":"2020021111361319900_B26","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.leukres.2016.07.007","article-title":"Impact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patients","volume":"48","author":"Dorer","year":"2016","journal-title":"Leuk Res"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/3\/530\/1634270\/advancesadv2019000268.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/3\/530\/1634270\/advancesadv2019000268.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T11:36:41Z","timestamp":1581421001000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/3\/530\/441050\/Sideeffects-profile-and-outcomes-of-ponatinib-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,11]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,2,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019000268","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,11]]}}}